Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
NCT04305548Phase 2Recruiting
- Sponsor
- Italian Sarcoma Group
- Start
- Sep 2021
- Primary completion
- Dec 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trabectedin in mesenchymal chondrosarcoma (MCS), sponsored by Italian Sarcoma Group. Started Sep 2021; status: recruiting.
02
Drugs
trabectedin
03
Conditions
mesenchymal chondrosarcoma (MCS)
Beyond the preview
Go deeper on NCT04305548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305548.